Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts. Show more

Location: 4 Kingsbury Avenue, Watertown, MA, 02472, United States | Website: https://www.enanta.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

188.6M

52 Wk Range

$4.09 - $13.37

Previous Close

$8.82

Open

$8.77

Volume

101,918

Day Range

$8.50 - $8.96

Enterprise Value

43.13M

Cash

204.1M

Avg Qtr Burn

-5.796M

Insider Ownership

6.55%

Institutional Own.

86.58%

Qtr Updated

06/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
MAVYRET (Glecaprevir) Details
HCV (Hepatitis C Virus)

Approved

Quarterly sales

Zelicapavir (EDP-938) Details
Respiratory syncytial virus

Susp. Mover™

Phase 2

Data readout

EDP-235 Details
Viral infection, COVID-19

Phase 2

Update

EDP-323 Details
Respiratory syncytial virus

Phase 2a

Update

EDP-305 (FXR Agonist) Details
Non-alcoholic steatohepatitis

Failed

Discontinued

Failed

Discontinued

ENP-297 (FXR inhibitor) Details
Non-alcoholic steatohepatitis

Failed

Discontinued